PRME
Prime Medicine·NASDAQ
--
--(--)
--
--(--)
PRME fundamentals
During Q4 2025, Prime Medicine (PRME) reported revenue of 838.00K, a YoY change of -61.61%. Net income was -46.08M, a YoY change of -9.00%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | 591.00K -- | -- -- | 209.00K -- | 2.18M -- | 1.45M +146.02% | 1.11M -- | 1.23M +486.12% | 838.00K -61.61% | 4.63M -- |
Sales and Services Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | 0 -- | 591.00K -- | 0 -- | 209.00K -- | 2.18M -- | 1.45M +146.02% | 1.11M -- | 1.23M +486.12% | 838.00K -61.61% | 4.63M -- |
Cost of Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 10.43M -- | 60.08M -- | 19.90M -- | 26.30M -- | 31.66M +203.59% | 38.69M -35.60% | 40.03M +101.19% | 45.26M +72.05% | 51.46M +62.56% | 68.04M +75.89% | 48.93M +22.23% | 55.67M +23.01% | 54.44M +5.79% | 46.41M -31.80% | 53.85M +10.04% | 54.49M -2.12% | 55.20M +1.39% | 49.45M +6.55% | 212.98M -- |
Selling, General and Administrative Expenses | 3.03M -- | 7.19M -- | 6.22M -- | 7.37M -- | 6.61M +118.30% | 9.63M +33.92% | 9.15M +47.13% | 10.66M +44.71% | 10.49M +58.78% | 13.08M +35.94% | 11.16M +21.91% | 12.60M +18.23% | 14.10M +34.40% | 12.30M -5.98% | 13.28M +19.05% | 13.12M +4.09% | 11.21M -20.52% | 14.74M +19.80% | 52.35M -- |
General and Administrative Expenses | -- -- | 13.92M -- | -- -- | -- -- | -- -- | 29.82M +114.16% | -- -- | -- -- | 10.49M -- | 13.08M -56.12% | 11.16M -- | 12.60M -- | 14.10M +34.40% | 12.30M -5.98% | 13.28M +19.05% | 13.12M +4.09% | 11.21M -20.52% | 14.74M +19.80% | 52.35M -- |
Research and Development Expenses | 7.40M -- | 52.89M -- | 13.68M -- | 18.94M -- | 25.05M +238.47% | 29.06M -45.05% | 30.88M +125.78% | 34.60M +82.68% | 40.97M +63.56% | 41.46M +42.66% | 37.77M +22.33% | 43.07M +24.49% | 40.34M -1.53% | 34.10M -17.74% | 40.56M +7.38% | 41.38M -3.94% | 43.99M +9.05% | 34.71M +1.77% | 160.64M -- |
Other Operating Expenses | 0 -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 13.50M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -10.43M -- | -60.08M -- | -19.90M -- | -26.30M -- | -31.66M -203.59% | -38.69M +35.60% | -40.03M -101.19% | -45.26M -72.05% | -51.46M -62.56% | -68.04M -75.89% | -48.34M -20.75% | -55.67M -23.01% | -54.23M -5.39% | -44.22M +35.01% | -52.39M -8.38% | -53.38M +4.12% | -53.97M +0.48% | -48.61M -9.92% | -208.35M -- |
Non-Operating Income (Loss) | -8.36M -- | -1.45M -- | -4.47M -- | -3.48M -- | 2.52M +130.13% | -783.00K +46.15% | 434.00K +109.70% | 2.90M +183.30% | 643.00K -74.45% | 2.40M +406.51% | 2.71M +525.35% | 211.00K -92.73% | 1.71M +166.56% | 1.95M -18.92% | 502.00K -81.50% | 786.00K +272.51% | 3.39M +97.84% | 2.53M +29.96% | 7.21M -- |
Gain (Loss) on Change in Fair Value | -- -- | -81.39M -- | -- -- | -- -- | -- -- | -8.13M +90.01% | -- -- | -- -- | 190.00K -- | -3.92M +51.82% | 1.17M -- | -1.93M -- | 1.10M +478.95% | -3.14M +19.77% | -1.06M -190.57% | -505.00K +73.77% | 2.21M +100.55% | -1.08M +65.56% | -437.00K -- |
Other Non-Operating Income (Loss) | -8.36M -- | 79.94M -- | -4.47M -- | -3.48M -- | 2.52M +130.13% | 7.34M -90.81% | 434.00K +109.70% | 2.27M +165.08% | 43.00K -98.29% | 5.83M -20.69% | 872.00K +100.92% | 1.52M -32.76% | -83.00K -293.02% | 3.55M -39.06% | 376.00K -56.88% | 548.00K -64.07% | 44.00K +153.01% | 2.53M -28.79% | 3.50M -- |
Net Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -635.00K -- | -410.00K -- | -491.00K -- | -676.00K -- | -611.00K +3.78% | -697.00K -70.00% | -1.54M -213.24% | -1.18M -74.85% | -743.00K -21.60% | -1.14M -63.70% | -1.08M +29.58% | -4.15M -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 635.00K -- | 410.00K -- | 491.00K -- | 676.00K -- | 611.00K -3.78% | 697.00K +70.00% | 1.54M +213.24% | 1.18M +74.85% | 743.00K +21.60% | 1.14M +63.70% | 1.08M -29.58% | 4.15M -- |
Pretax Income From Continuing Operations | -18.78M -- | -61.53M -- | -24.37M -- | -29.79M -- | -29.14M -55.14% | -39.47M +35.85% | -39.60M -62.48% | -42.35M -42.18% | -50.82M -74.40% | -65.64M -66.32% | -45.63M -15.22% | -55.46M -30.95% | -52.52M -3.35% | -42.28M +35.60% | -51.89M -13.73% | -52.59M +5.17% | -50.58M +3.69% | -46.08M -9.00% | -201.14M -- |
Income Tax Expense | -2.37M -- | 1.38M -- | -532.00K -- | -442.00K -- | 212.00K +108.95% | -186.00K -113.47% | -202.00K +62.03% | 31.00K +107.01% | -108.00K -150.94% | -- -- | 134.00K +166.34% | -134.00K -532.26% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Current Income Tax | -- -- | 138.00K -- | -- -- | -- -- | -- -- | 16.00K -88.41% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Deferred Income Tax | -- -- | -624.00K -- | -- -- | -- -- | -- -- | -964.00K -54.49% | -- -- | -- -- | -- -- | -279.00K +71.06% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -16.41M -- | -62.91M -- | -23.84M -- | -29.35M -- | -29.35M -78.83% | -39.28M +37.56% | -39.40M -65.26% | -42.38M -44.42% | -50.71M -72.77% | -65.64M -67.10% | -45.76M -16.15% | -55.33M -30.53% | -52.52M -3.57% | -42.28M +35.60% | -51.89M -13.39% | -52.59M +4.95% | -50.58M +3.69% | -46.08M -9.00% | -201.14M -- |
Net Income Attributable to Minority Interests | 0 -- | -1.47M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Owners of the Company | -16.41M -- | -61.44M -- | -23.84M -- | -29.35M -- | -29.35M -78.83% | -39.28M +36.07% | -39.40M -65.26% | -42.38M -44.42% | -50.71M -72.77% | -65.64M -67.10% | -45.76M -16.15% | -55.33M -30.53% | -52.52M -3.57% | -42.28M +35.60% | -51.89M -13.39% | -52.59M +4.95% | -50.58M +3.69% | -46.08M -9.00% | -201.14M -- |
Preferred Stock Dividends | 6.36M -- | 7.83M -- | 6.22M -- | 6.29M -- | 6.36M -0.02% | 1.31M -83.22% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Common Stockholders | -22.77M -- | -69.27M -- | -30.06M -- | -35.64M -- | -35.71M -56.80% | -40.60M +41.40% | -39.40M -31.04% | -42.38M -18.92% | -50.71M -41.99% | -65.64M -61.69% | -45.76M -16.15% | -55.33M -30.53% | -52.52M -3.57% | -42.28M +35.60% | -51.89M -13.39% | -52.59M +4.95% | -50.58M +3.69% | -46.08M -9.00% | -201.14M -- |
Other Comprehensive Income | 25.00K -- | -18.00K -- | -5.00K -- | -118.00K -- | -304.00K -1316.00% | 70.00K +488.89% | 179.00K +3680.00% | -63.00K +46.61% | 119.00K +139.14% | 134.00K +91.43% | -80.00K -144.69% | 24.00K +138.10% | 92.00K -22.69% | -20.00K -114.93% | -16.00K +80.00% | 5.00K -79.17% | 43.00K -53.26% | 49.00K +345.00% | 81.00K -- |
Total Comprehensive Income | -16.39M -- | -62.93M -- | -23.84M -- | -29.47M -- | -29.65M -80.96% | -39.21M +37.69% | -39.22M -64.47% | -42.45M -44.06% | -50.59M -70.60% | -65.51M -67.06% | -45.84M -16.89% | -55.30M -30.28% | -52.43M -3.63% | -42.30M +35.43% | -51.91M -13.23% | -52.59M +4.91% | -50.54M +3.60% | -46.03M -8.83% | -201.06M -- |
Total Comprehensive Income Attributable to Owners of the Company | -16.39M -- | -62.93M -- | -23.84M -- | -29.47M -- | -29.65M -80.96% | -39.21M +37.69% | -39.22M -64.47% | -42.45M -44.06% | -50.59M -70.60% | -65.51M -67.06% | -45.84M -16.89% | -55.30M -30.28% | -52.43M -3.63% | -42.30M +35.43% | -51.91M -13.23% | -52.59M +4.91% | -50.54M +3.60% | -46.03M -8.83% | -201.06M -- |
Basic EPS | -1.52 -- | -- -- | -1.58 -- | -1.76 -- | -1.61 -5.92% | -0.42 -- | -0.44 +72.15% | -0.47 +73.30% | -0.55 +65.84% | -0.67 -59.52% | -0.44 -- | -0.46 +2.13% | -0.44 +20.00% | -0.32 +52.24% | -0.4 +9.09% | -0.41 +10.87% | -0.32 +27.27% | -0.26 +18.75% | -1.39 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.55 -- | -- -- | -0.44 -- | -0.46 -- | -0.44 +20.00% | -- -- | -0.4 +9.09% | -0.41 +10.87% | -0.32 +27.27% | -- -- | -- -- |
Diluted EPS | -1.52 -- | -- -- | -1.58 -- | -1.76 -- | -1.61 -5.92% | -- -- | -0.44 +72.15% | -0.47 +73.30% | -0.55 +65.84% | -- -- | -0.44 -- | -0.46 +2.13% | -0.44 +20.00% | -- -- | -0.4 +9.09% | -0.41 +10.87% | -0.32 +27.27% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.55 -- | -- -- | -0.44 -- | -0.46 -- | -0.44 +20.00% | -- -- | -0.4 +9.09% | -0.41 +10.87% | -0.32 +27.27% | -- -- | -- -- |
You can ask Aime
What is Prime Medicine's gross profit margin?What is the revenue and EPS growth rate for Prime Medicine year over year?What is Prime Medicine's latest dividend and current dividend yield?What were the key takeaways from Prime Medicine’s earnings call?Did Prime Medicine beat or miss consensus estimates last quarter?What factors drove the changes in Prime Medicine's revenue and profit?What guidance did Prime Medicine's management provide for the next earnings period?What is the market's earnings forecast for Prime Medicine next quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
